Kozy Bio CT053 Whole human anti-BCMA car car T cell injection obtained FDA approval
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Cozi E
Pharmaceutical(http://(Shanghai) LimitedCompany(http://announced that its independent research and development in the researchProduct(http://-CT053 all-human anti-BCMA car T cell injection for the treatment of recurrent recurrent multiple myelomanew drug(http://clinicaltrial(http://
)The Drug(http://Regulatory Authority (
FDA(http://) has been notified of the product's entry into clinical trialsCT053 CAR-BCMA T is an innovativedrug(http://developed by Kozy Bio, and is a T-cell modified with a metoidal antibody-targeted B-cell mature antigen (BCMA) chimeric antigen receptor (BCMA), with the main target indication for recurrent/difficult to treat multiple myelomathe clinical trial was approved in the U.S., the second country or region to obtain a clinical license for the product after it was implicitly licensed by China's National Drug Administration (NMPA) on February 27, 2019this approval is also the first time that China's original research CAR-T project in the United States independent lying for IND, and successfully obtained FDA approval
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
